{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:29Z","timestamp":1786980269942,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00482-022-00648-8","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T03:02:21Z","timestamp":1651028541000},"page":"168-174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Galcanezumab bei episodischem und chronischem Clusterkopfschmerz","Galcanezumab for episodic and chronic cluster headache"],"prefix":"10.1007","volume":"37","author":[{"given":"Heiko","family":"Pohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagny","family":"Holle-Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.","family":"Broicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inka","family":"Schwerdtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas R.","family":"Gantenbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"648_CR1","unstructured":"Andr\u00e9e C, Barone-Kaganas I, Biethahn S et al (2019) Therapieempfehlungen f\u00fcr prim\u00e4re Kopfschmerzen. 10., vollst\u00e4ndig \u00fcberarbeitete Auflage. https:\/\/www.headache.ch\/download\/Content_attachments\/FileBaseDoc\/SKG_Therapieempfehlungen_2018_DE_15_WEB.pdf. Zugegriffen: 15.04.2022"},{"issue":"3","key":"648_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1212\/WNL.58.3.354","volume":"58","author":"A Bahra","year":"2002","unstructured":"Bahra\u00a0A et\u00a0al (2002) Cluster headache: a prospective clinical study with diagnostic implications. Neurology 58(3):354\u2013361","journal-title":"Neurology"},{"key":"648_CR3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.joca.2014.01.009","volume":"22","author":"RJ Benschop","year":"2014","unstructured":"Benschop\u00a0RJ, Collins\u00a0EC, Darling\u00a0RJ et al (2014) Development of a\u00a0novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthritis Cartilage 22:578\u2013585","journal-title":"Osteoarthritis Cartilage"},{"issue":"8","key":"648_CR4","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1177\/0333102419856607","volume":"39","author":"IF de Coo","year":"2019","unstructured":"de Coo\u00a0IF, Marin\u00a0JC, Silberstein\u00a0SD et al (2019) Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a meta-analysis. Cephalalgia 39(8):967\u2013977","journal-title":"Cephalalgia"},{"issue":"9","key":"648_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick\u00a0DW, Goadsby\u00a0PJ, Egilius\u00a0LH, Spierings\u00a0ELH et al (2014) Safety and efficacy of LY2951742, a\u00a0monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a\u00a0phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13(9):885\u2013892","journal-title":"Lancet Neurol"},{"key":"648_CR6","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0333102420905321","volume":"40","author":"DW Dodick","year":"2020","unstructured":"Dodick\u00a0DW, Goadsby\u00a0PJ, Lucas\u00a0C et al (2020) Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3\u2011month double-blind treatment. Cephalalgia 40:935\u2013948","journal-title":"Cephalalgia"},{"key":"648_CR7","volume-title":"Assessment report emgality","author":"European Medicines Agency","year":"2020","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) (2020) Assessment report emgality (Procedure No. EMEA\/H\/C\/004648\/X\/0004)"},{"issue":"11","key":"648_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/jnnp.2007.124206","volume":"78","author":"S Evers","year":"2007","unstructured":"Evers\u00a0S, Fischera\u00a0M, May\u00a0A et\u00a0al (2007) Prevalence of cluster headache in Germany: results of the epidemiological DMKG study. J\u00a0Neurol Neurosurg Psychiatry 78(11):1289\u20131290","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"648_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1177\/0333102415607070","volume":"36","author":"C Gaul","year":"2016","unstructured":"Gaul\u00a0C, Diener\u00a0HC, Silver\u00a0N et al (2016) Non-invasive vagus nerve stimulation for PREVention and acute treatment of chronic cluster headache (PREVA): a randomised controlled study. Cephalalgia 36(6):534\u2013546","journal-title":"Cephalalgia"},{"key":"648_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1813440","volume":"381","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby\u00a0PJ, Dodick\u00a0DW, Leone\u00a0M et\u00a0al (2019) Trial of galcanezumab in prevention of episodic cluster headache. N\u00a0Engl J Med 381:132\u2013141","journal-title":"N Engl J Med"},{"issue":"3","key":"648_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/brain\/117.3.427","volume":"117","author":"PJ Goadsby","year":"1994","unstructured":"Goadsby\u00a0PJ, Edvinsson\u00a0L (1994) Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 117(3):427\u2013434","journal-title":"Brain"},{"issue":"1","key":"648_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (2018) The international classification of headache disorders. Cephalalgia 38(1):1\u2013211","journal-title":"Cephalalgia"},{"issue":"4","key":"648_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0271678X17733655","volume":"39","author":"J Hoffmann","year":"2019","unstructured":"Hoffmann\u00a0J, Baca\u00a0SM, Akerman\u00a0S (2019) Neurovascular mechanisms of migraine and cluster headache. J\u00a0Cereb Blood Flow Metab 39(4):573\u2013594","journal-title":"J Cereb Blood Flow Metab"},{"key":"648_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0333102420949858","volume":"41","author":"K Kamm","year":"2020","unstructured":"Kamm\u00a0K, Straube\u00a0A, Ruscheweyh\u00a0R (2020) Baseline tear fluid CGRP is elevated in active cluster headache patients as long as they have not taken attack abortive medication. Cephalalgia. https:\/\/doi.org\/10.1177\/0333102420949858","journal-title":"Cephalalgia"},{"issue":"2","key":"648_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jcph.1511","volume":"60","author":"W Kielbasa","year":"2020","unstructured":"Kielbasa\u00a0W, Quinlan\u00a0T (2020) Population pharmacokinetics of galcanezumab, an anti-CGRP antibody, following subcutaneous dosing to healthy individuals and patients with migraine. J\u00a0Clin Pharmacol 60(2):229\u2013239","journal-title":"J Clin Pharmacol"},{"key":"648_CR16","volume-title":"Impact of galcanezumab on total pain burden: findings from a\u00a0phase III, randomized, double-blind, placebo-controlled study in patients with episodic cluster headache","author":"D Kudrow","year":"2019","unstructured":"Kudrow\u00a0D, Andrews\u00a0JS, Rettiganti\u00a0M et al (2019) Impact of galcanezumab on total pain burden: findings from a\u00a0phase III, randomized, double-blind, placebo-controlled study in patients with episodic cluster headache (AHS 2019, Poster P248LB)"},{"key":"648_CR17","volume-title":"Post-hoc analyses from a\u00a0phase III, randomized, double-blind, placebo-controlled study of galcanezumab in patients with episodic cluster headache","author":"D Kudrow","year":"2019","unstructured":"Kudrow\u00a0D, Oakes\u00a0T, Bardos\u00a0J et al (2019) Post-hoc analyses from a\u00a0phase III, randomized, double-blind, placebo-controlled study of galcanezumab in patients with episodic cluster headache (AHS 2019, Poster P259LB)"},{"key":"648_CR18","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1111\/head.14011","volume":"60","author":"D Kudrow","year":"2020","unstructured":"Kudrow\u00a0D, Andrews\u00a0JS, Rettiganti\u00a0M et\u00a0al (2020) Treatment outcomes in patients treated with galcanezumab vs placebo: post hoc analyses from a\u00a0phase 3 randomized study in patients with episodic cluster headache. Headache 60:2254\u20132264","journal-title":"Headache"},{"issue":"1","key":"648_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/head.14234","volume":"62","author":"MJ L\u00e1inez","year":"2021","unstructured":"L\u00e1inez\u00a0MJ, Schoenen\u00a0J, Stroud\u00a0C et\u00a0al (2021) Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15\u00a0months of galcanezumab treatment. Headache. https:\/\/doi.org\/10.1111\/head.14234","journal-title":"Headache"},{"issue":"2","key":"648_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1468-2982.2004.00817.x","volume":"25","author":"E Loder","year":"2005","unstructured":"Loder\u00a0E, Goldstein\u00a0R, Biondi\u00a0D (2005) Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia 25(2):124\u2013131","journal-title":"Cephalalgia"},{"issue":"5","key":"648_CR21","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/brain\/awf118","volume":"125","author":"MS Matharu","year":"2002","unstructured":"Matharu\u00a0MS, Goadsby\u00a0PJ (2002) Persistence of attacks of cluster headache after trigeminal nerve root section. Brain 125(5):976\u2013984","journal-title":"Brain"},{"issue":"3","key":"648_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1055\/s-0037-1616368","volume":"35","author":"A May","year":"2016","unstructured":"May\u00a0A, Evers\u00a0S, Br\u00f6ssner\u00a0G et al (2016) Leitlinie zur Diagnostik, Therapie und Prophylaxe von Cluster-Kopfschmerz, anderen trigeminoautonomen Kopfschmerzen, schlafgebundenem Kopfschmerz und idiopathisch stechenden Kopfschmerzen. \u00dcberarbeitete Therapieempfehlungen der Deutschen Migr\u00e4ne- und Kopfschmerzgesellschaft in Zusammenarbeit mit der DGN, \u00d6KSG, SKG. Nervenheilkunde 35(3):137\u2013151","journal-title":"Nervenheilkunde"},{"issue":"10","key":"648_CR23","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/j.1468-1331.2006.01566.x","volume":"13","author":"A May","year":"2006","unstructured":"May\u00a0A, Leone\u00a0M, \u00c1fra\u00a0J et al (2006) EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 13(10):1066\u20131077","journal-title":"Eur J Neurol"},{"issue":"4","key":"648_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/0333102414539057","volume":"35","author":"L Neeb","year":"2015","unstructured":"Neeb\u00a0L, Anders\u00a0L, Euskirchen\u00a0P et\u00a0al (2015) Corticosteroids alter CGRP and melatonin release in cluster headache episodes. Cephalalgia 35(4):317\u2013326","journal-title":"Cephalalgia"},{"issue":"7","key":"648_CR25","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1046\/j.1468-2982.2003.00531.x","volume":"23","author":"AI Nilsson Remahl","year":"2003","unstructured":"Nilsson Remahl\u00a0AI, Laudon Meyer\u00a0E, Cordonnier\u00a0C et\u00a0al (2003) Placebo response in cluster headache trials: a\u00a0review. Cephalalgia 23(7):504\u2013510","journal-title":"Cephalalgia"},{"issue":"1","key":"648_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1474-4422(20)30363-X","volume":"20","author":"M Obermann","year":"2021","unstructured":"Obermann\u00a0M, N\u00e4gel\u00a0S, Ose\u00a0C et al (2021) Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a\u00a0multicentre, double-blind, randomised controlled trial. Lancet Neurol 20(1):29\u201337","journal-title":"Lancet Neurol"},{"key":"648_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1526-4610.2011.02028.x","volume":"52","author":"TD Rozen","year":"2012","unstructured":"Rozen\u00a0TD, Fishman\u00a0RS (2012) Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache 52:99\u2013113","journal-title":"Headache"},{"issue":"14","key":"648_CR28","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/0333102420949866","volume":"40","author":"R Ruscheweyh","year":"2020","unstructured":"Ruscheweyh\u00a0R, Broessner\u00a0G, Go\u00dfrau\u00a0G et al (2020) Effect of calcitonin gene-related peptide (\u2011receptor) antibodies in chronic cluster headache: results from a\u00a0retrospective case series support individual treatment attempts. Cephalalgia 40(14):1574\u20131584","journal-title":"Cephalalgia"},{"issue":"5","key":"648_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/0333102419837154","volume":"39","author":"A Snoer","year":"2019","unstructured":"Snoer\u00a0A, Vollesen\u00a0ALH, Beske\u00a0RP et al (2019) Calcitonin-gene related peptide and disease activity in cluster headache. Cephalalgia 39(5):575\u2013584","journal-title":"Cephalalgia"},{"key":"648_CR30","unstructured":"Teva Pharmaceutical Industries Ltd (2018) Teva provides update on clinical trial of fremanezumab for use in chronic cluster headache. https:\/\/www.tevapharm.com\/news-and-media\/latest-news\/teva-provides-update-on-clinical-trial-of-fremanezumab-for-use-in-chronic-cluster-headache\/. Zugegriffen: 15.04.2022"},{"key":"648_CR31","unstructured":"Teva Pharmaceutical Industries Ltd (2019) Teva announces update on fremanezumab clinical development for use in episodic cluster headache. https:\/\/www.tevapharm.com\/news-and-media\/latest-news\/teva-announces-update-on-fremanezumab-clinical-development-for-use-in-episodic-cluster-headache\/. Zugegriffen: 15.04.2022"},{"issue":"1","key":"648_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11916-002-0026-5","volume":"6","author":"P Torelli","year":"2002","unstructured":"Torelli\u00a0P, Manzoni\u00a0GC (2002) What predicts evolution from episodic to chronic cluster headache? Curr Pain Headache Rep 6(1):65\u201370","journal-title":"Curr Pain Headache Rep"},{"key":"648_CR33","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamaneurol.2018.1675","volume":"75","author":"ALH Vollesen","year":"2018","unstructured":"Vollesen\u00a0ALH, Snoer\u00a0A, Beske\u00a0RP et al (2018) Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurol 75:1187\u20131197","journal-title":"JAMA Neurol"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-022-00648-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-022-00648-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-022-00648-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:08:03Z","timestamp":1685434083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-022-00648-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1007\/s00482-022-00648-8","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0Pohl erhielt in den letzten Jahren Honorare f\u00fcr Referate und Beratung von Eli Lilly, Novartis und Teva\/Mepha. A.R.\u00a0Gantenbein erhielt in den letzten Jahren Honorare f\u00fcr Referate und Beratung von Allergan, Almirall, Curatis, Eli Lilly, Novartis, Pfizer, Roche und Teva\/Mepha. D.\u00a0Holle-Lee erhielt in den letzten Jahren Honorare f\u00fcr Referate und Beratung von Allergan, Hormosan, Eli Lilly, Novartis und Teva. C.\u00a0Gaul erhielt in den letzten 3\u00a0Jahren Honorare f\u00fcr Vortr\u00e4ge und Advisory Boards von Allergan Pharma, Teva-Ratiopharm, Eli Lilly, Novartis Pharma, Hormosan Pharma, Gr\u00fcnenthal, Lundbeck, Weber & Weber, Perfood und Sanofi. C.\u00a0Gaul besitzt keine Aktien oder Anteile pharmazeutischer Unternehmen. C.\u00a0Gaul ist ehrenamtlicher Generalsekret\u00e4r der Deutschen Migr\u00e4ne- und Kopfschmerzgesellschaft. I.\u00a0Schwerdtner und S.D.\u00a0Broicher sind Mitarbeiterinnen von Eli Lilly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}